The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Antibodies to Remicade Cross-React with Biosimilar Remsima

Antibodies to Remicade Cross-React with Biosimilar Remsima

May 28, 2015 • By Will Boggs, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Antibodies to infliximab in patients with inflammatory bowel disease (IBD) treated with Janssen’s Remicade cross-react with the biosimilar Remsima from Celltrion (distributed as Inflectra by Hospira in the U.S.), researchers from Israel report.

You Might Also Like
  • Remicade Antibodies Cross-React to Biosimilars
  • Infliximab Biosimilar Cross Reacts to Infliximab Antibodies; Plus Treat-to-Target Strategy Promising for Treating RA with bDMARDs
  • FDA Advisory Panel Strongly Backs Biosimilar Form of Remicade
Also By This Author
  • Alcohol Use Complicates Chronic Disease Management in Teens

“The cross-reactivity of anti-Remicade antibodies with Remsima attests to shared immune triggering points (epitopes) on these two agents, and may therefore provide a further level of evidence to reassure physicians about the similarity between this particular biosimilar and the originator infliximab,” said Dr. Shomron Ben-Horin from Sackler School of Medicine, Tel-Aviv University in Ramat-Gan, Israel.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“The toll to pay for this similarity is that physicians should refrain from switching to Remsima (in) patients with anti-Remicade antibodies, especially if they have high-titer antibodies,” he told Reuters Health by e-mail.

In studies of rheumatoid arthritis and ankylosing spondylitis, rates of antidrug antibodies to Remicade and Remsima were similar, Dr. Ben-Horin’s team writes in Gut, online April 20.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

But there have been no direct studies to investigate cross-immunogenicity of the two compounds, particularly in IBD patients, they add.

The researchers studied 86 patients to see if antibodies elicited by Remicade would cross-react with and recognize Remsima to a similar extent. None of the patients had ever been exposed to Remsima.

All sera that tested positive to anti-Remicade antibodies were also cross-reactive with Remsima, the team found. Conversely, all sera that tested negative to anti-Remicade antibodies were also negative for anti-Remsima antibodies.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

In functional assays, anti-Remicade-positive sera inhibited Remicade and Remsima TNF-alpha binding to a similar extent, whereas anti-Remicade-negative sera inhibited neither Remicade nor Remsima TNF-alpha binding capacity.

Seven anti-adalimumab-positive sera from IBD patients never exposed to Remicade had no detectable anti-Remicade or anti-Remsima cross-reacting antibodies.

“These results suggest that these two infliximab monoclonal antibody drugs are similarly recognized by the immune system in patients with inflammatory bowel disease,” Dr. Ben-Horin said. “This implies that the rate of immunogenicity problems manifesting as loss of response or infusion reactions is probably not likely to be significantly different between Remicade or Remsima in clinical practice.”

“While these results are reassuring and in line with the findings of the head-to-head trials in rheumatoid arthritis and ankylosing spondylitis, pharmacovigilance studies are still warranted and are indeed ongoing to monitor the safety of this biosimilar in clinical practice,” he added.

Dr. Xavier Roblin from the department of gastroenterology at CHU Saint-Etienne, France, told Reuters Health by e-mail, “We must await interventional studies and long-term follow-up to conclude comparable safety and efficacy of biosimilar (drugs) in IBD patients.”

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: biosimilar, Celltrion, infliximab, Remsima

You Might Also Like:
  • Remicade Antibodies Cross-React to Biosimilars
  • Infliximab Biosimilar Cross Reacts to Infliximab Antibodies; Plus Treat-to-Target Strategy Promising for Treating RA with bDMARDs
  • FDA Advisory Panel Strongly Backs Biosimilar Form of Remicade
  • Rheumatology Drug Updates: Infliximab Biosimilar Cross Reacts to Infliximab Antibodies

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)